Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. (February 2015)

• Record Type: Journal Article
• Authors: Popat, Sanjay; Mellemgaard, Anders; Fahrbach, Kyle; Martin, Alison; Rizzo, Maria; Kaiser, Rolf; Griebsch, Ingolf; Reck, Martin
• Is Part Of: Future oncology. Volume 11:Number 3(2015)
• Page Start: 409
• Page End: 420
• Publication Date: 2015-02
• Subjects: adenocarcinoma -- chemotherapy -- nintedanib -- NSCLC -- second-line treatment; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.14.290
• Languages: English
• ISSNs: 1479-6694

Abstract

ABSTRACT : Background: Nintedanib plus docetaxel has proven an overall survival benefit over docetaxel monotherapy in second-line treatment of non-small-cell lung cancer of adenocarcinoma histology in the LUME-Lung 1 pivotal trial. No published trials have previously compared nintedanib plus docetaxel with agents – other than docetaxel – that are approved second-line treatments for non-small-cell lung cancer.Methods: The relative efficacy of nintedanib plus docetaxel versus second-line agents was evaluated by conducting a network meta-analysis of progression-free survival and overall survival.Results: Nine suitable studies were identified. The estimated probability of nintedanib plus docetaxel being the best treatment with regard to overall survival was 70% (versus 16% for pemetrexed, 10% for docetaxel and 3% for erlotinib). Results for progression-free survival were similar.Conclusion: In patients with advanced non-small-cell lung cancer of adenocarcinoma histology, results suggest that nintedanib plus docetaxel offers clinical benefit compared with docetaxel alone, when used as second-line treatment, and suggests that this combination may also add clinical benefit compared with erlotinib in this patient group.